The past year has brought to light both the promise and the frustration of developing new drugs to treat melanoma , the most deadly form of skin cancer. Early clinical tests of a candidate drug aimed at a crucial cancer-causing gene revealed impressive results in patients whose cancers resisted all currently available… Continue
Added by Peter Hofland, PhD on November 24, 2010 at 11:30am —
TGen Clinical Research Services (TCRS) is testing a new drug that may offer broad potential to treat solid tumors. Clinical trials of the drug TH-302, an anticancer agent in clinical development by Threshold Pharmaceuticals (1300 Seaport Blvd, Suite 500, Redwood City, CA 94063), are being conducted at the Mayo Clinic in Arizona by TGen Clinical Research Services, a partnership of Translational Genomics Research Institute (TGen) and Scottsdale Healthcare Corp.
Dr. Glen… Continue
Added by Peter Hofland, PhD on January 29, 2009 at 5:00pm —